EUVIMEDEUVIMED entdecken
Open Access

mTORC1 Inhibitor Rapamycin Inhibits Growth of Cerebral Cavernous Malformation in Adult Mice

Lun Li, Aileen A Ren iD, Siqi Gao iD, Yourong S Su, Jisheng Yang, Jenna Bockman, Patricia Mericko-Ishizuka iD, Joanna Griffin iD, Robert Shenkar iD, Roberto Alcazar iD, Thomas Moore, Rhonda Lightle iD und 5 weitere

Stroke · 2023-11 · 54 (11) · 2906-2917

DOI: 10.1161/strokeaha.123.044108 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stroke, 2023-11. Verfasst von Lun Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Institute and Department of Medicine, Perelman School of Medicine (L.L., A.A.R., S.G., J.Y., J.B., P.M.-I., J.G., M.L.K.), University …. Hauptthemen laut MEDLINE: Hemangioma, Cavernous, Central Nervous System. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NHLBI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cerebral cavernous malformations (CCMs) are vascular malformations that frequently cause stroke. CCMs arise due to loss of function in one of the genes that encode the CCM complex, a negative regulator of MEKK3-KLF2/4 signaling in vascular endothelial cells. Gain-of-function mutations in PIK3CA (encoding the enzymatic subunit of the PI3K (phosphoinositide 3-kinase) pathway associated with cell growth) synergize with CCM gene loss-of-function to generate rapidly growing lesions. METHODS: We recently developed a model of CCM formation that closely reproduces key events in human CCM formation through inducible CCM loss-of-function and PIK3CA gain-of-function in mature mice. In the present study, we use this model to test the ability of rapamycin, a clinically approved inhibitor of the PI3K effector mTORC1, to treat rapidly growing CCMs. RESULTS: We show that both intraperitoneal and oral administration of rapamycin arrests CCM growth, reduces perilesional iron deposition, and improves vascular perfusion within CCMs. CONCLUSIONS: Our findings further establish this adult CCM model as a valuable preclinical model and support clinical testing of rapamycin to treat rapidly growing human CCMs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemangioma, Cavernous, Central Nervous SystemAnimalsHumansAdultMiceEndothelial CellsSirolimusPhosphatidylinositol 3-KinasesClass I Phosphatidylinositol 3-Kinases

Stichwörter der Autor:innen

humansmicemutationperfusionsirolimusstroke

Substanzen

SirolimusPhosphatidylinositol 3-KinasesClass I Phosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Cardiovascular Institute and Department of Medicine, Perelman School of Medicine (L.L., A.A.R., S.G., J.Y., J.B., P.M.-I., J.G., M.L.K.), University of Pennsylvania, Philadelphia.
  • Department of Neurosurgery, Perelman School of Medicine, Hospital of the University of Pennsylvania (L.L., Y.S.S., J.-K.B.), University of Pennsylvania, Philadelphia.
  • Neurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, The University of Chicago Medicine and Biological Sciences, IL (R.S., R.A., T.M., R.L., D.D., I.A.A.).
  • Department of Molecular Genetics and Microbiology, School of Medicine, Duke University, Durham, NC (D.A.M.).

ORCID-Profile: Aileen A Ren, Siqi Gao, Patricia Mericko-Ishizuka, Joanna Griffin, Robert Shenkar, Roberto Alcazar, Rhonda Lightle, Dorothy DeBiasse, Issam A Awad, Douglas A Marchuk, Mark L Kahn, Jan-Karl Burkhardt

Förderung

  • NINDS NIH HHS
  • NHLBI NIH HHS
  • NIH HHS

Zitieren

APA

Li, L., Ren, A. A., Gao, S., Su, Y. S., Yang, J., Bockman, J., Mericko-Ishizuka, P., Griffin, J., Shenkar, R., Alcazar, R., Moore, T., Lightle, R., DeBiasse, D., Awad, I. A., Marchuk, D. A., Kahn, M. L., & Burkhardt, J. K. (2023). mTORC1 Inhibitor Rapamycin Inhibits Growth of Cerebral Cavernous Malformation in Adult Mice. Stroke, 54(11), 2906-2917. https://doi.org/10.1161/strokeaha.123.044108

Vancouver

Li L, Ren AA, Gao S, Su YS, Yang J, Bockman J, et al. mTORC1 Inhibitor Rapamycin Inhibits Growth of Cerebral Cavernous Malformation in Adult Mice. Stroke. 2023;54(11):2906-2917. doi:10.1161/strokeaha.123.044108

BibTeX
@article{Li2023,
  author = {Li, Lun and Ren, Aileen A and Gao, Siqi and Su, Yourong S and Yang, Jisheng and Bockman, Jenna and Mericko-Ishizuka, Patricia and Griffin, Joanna and Shenkar, Robert and Alcazar, Roberto and Moore, Thomas and Lightle, Rhonda and DeBiasse, Dorothy and Awad, Issam A and Marchuk, Douglas A and Kahn, Mark L and Burkhardt, Jan-Karl},
  title = {mTORC1 Inhibitor Rapamycin Inhibits Growth of Cerebral Cavernous Malformation in Adult Mice},
  journal = {Stroke},
  year = {2023},
  volume = {54},
  number = {11},
  pages = {2906--2917},
  doi = {10.1161/strokeaha.123.044108}
}
Kostenlos starten →